April 21, 2022 -- Artiva Biotherapeutics entered into an agreement with Merck to evaluate the therapeutic potential of Artiva's clinical-grade AB-101 natural killer (NK) cells from its AlloNK platform for assessment in combination with tri-specific NK-cell engager candidates.
The collaboration leverages Artiva's off-the-shelf allogeneic NK cell manufacturing platform, along with its proprietary CAR-NK technology, and includes two CAR-NK programs.
The companies entered into a collaboration and exclusive license agreement in January 2021 for the CAR-NK cells' discovery, development, manufacture, and commercialization. Artiva supports large-scale production and cryopreservation of off-the-shelf allogeneic NK and CAR-NK therapeutics.
No financial details were disclosed.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
